Antagonists of IAP-SHPS1 interaction
View Patent ↗Provided herein is technology relating to antagonists that inhibit, reduce, or minimize the interaction of integrin associated protein (IAP) with Src homology 2 (SH2) domain-containing protein tyrosine phosphatase substrate 1 (SHPS1) and particularly, but not exclusively, to compositions comprising such antagonists and methods of treatment comprising administering such antagonists.
1. A monoclonal antibody that specifically binds an epitope within amino acids 71-80 of the human integrin associated protein (IAP) and is an antagonist of IAP to Src homology 2 (SH2) domain-containing protein tyrosine phosphatase substrate 1 (SHPS-1) binding.
2. The antibody of claim 1 , coupled to a detectable group.
3. The antibody of claim 1 , coupled to a therapeutic group.
4. The antibody of claim 1 , wherein the antibody is a humanized antibody.
5. The antibody of claim 1 , wherein the antibody does not disrupt IAP binding to a 63 protein.
6. A pharmaceutical formulation comprising the antibody of claim 1 in a pharmaceutically acceptable carrier.
7. The antibody of claim 1 , wherein the antibody is selected from the group consisting of (a) the monoclonal antibody produced by the hybridoma cell line having ATCC accession number PTA-13161, and (b) a monoclonal antibody that competes for binding to the same epitope as the epitope bound by a monoclonal antibody produced by the hybridoma cell line having ATCC accession number PTA-13161.
8. The antibody of claim 7 , coupled to a detectable group.
9. The antibody of claim 7 , coupled to a therapeutic group.
10. The antibody of claim 7 , wherein the antibody is a humanized antibody.
11. A pharmaceutical formulation comprising the antibody of claim 7 in a pharmaceutically acceptable carrier.
12. A monoclonal antibody produced by the hybridoma cell line having ATCC accession number PTA-13161.
13. The antibody of claim 12 , coupled to a detectable group.
14. The antibody of claim 12 , coupled to a therapeutic group.
15. The antibody of claim 12 , wherein the antibody is a humanized antibody.
16. A pharmaceutical formulation comprising the antibody of claim 12 in a pharmaceutically acceptable carrier.
17. An antibody selected from the group consisting of (a) the monoclonal antibody produced by the hybridoma cell line having ATCC accession number PTA-13161, and (b) a monoclonal antibody that competes for binding to IAP with a monoclonal antibody produced by the hybridoma cell line having ATCC accession number PTA-13161.